Predictors of relapse in MOG antibody associated disease: a cohort study.
Saif HudaDaniel WhittamRichard JacksonVenkatraman KarthikeayanPatricia KellySam LinakerKerry MutchRachel KneenMark WoodhallKaty MurrayDavid HuntPatrick WatersAnu JacobPublished in: BMJ open (2021)
Male patients with spinal cord involvement at disease onset have a lower risk of relapsing disease and longer latency to first relapse. Steroid treatment for at least 1 month at first attack was also associated with a monophasic disease course. MOG-antibody negative seroconversion was associated with a lower risk of relapse and may help inform treatment decisions and duration.